Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

Soohyun Hwang(Samsung Medical Center), Se‐Hoon Lee(Samsung Medical Center)
Translational Lung Cancer Research
November 16, 2021
10.21037/tlcr-21-691
Cited by 15

Related Papers

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2024|233
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
|Journal of Clinical Oncology|2023|224
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
|Journal of Clinical Oncology|2024|131